Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies

EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

Now Viewing

EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

Video content above is prompted by the following questions:

• Briefly review the CARTITUDE-4 trial that led to cilta-cel’s approval in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).
  • Please comment on the patient population – intention-to-treat vs patients treated.
  • What was the rationale for the difference? How does it affect your interpretation of the data?
  • How did the safety outcomes compare with other CARTITUDE trials?
  • Please share your real-world experience.
• Please review data from KarMMa-3, which led to ide-cel’s approval in earlier lines of therapy for R/R MM.
  • What are thoughts on the efficacy and safety outcomes?
  • Please share your real-world experience. 
• How do these approvals impact the current and future treatment landscape of R/R MM?
  • How might you choose one over the other?
  • How does it address an unmet need?